MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Zai Lab Ltd ADR

Fermé

SecteurSoins de santé

35.46 0.74

Résumé

Variation du prix de l'action

24h

Actuel

Min

34.84

Max

35.48

Chiffres clés

By Trading Economics

Revenu

33M

-48M

Ventes

-2.6M

106M

Marge bénéficiaire

-45.487

Employés

1,869

EBITDA

19M

-56M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+64.93% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

475M

3.9B

Ouverture précédente

34.72

Clôture précédente

35.46

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Zai Lab Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 juil. 2025, 23:56 UTC

Acquisitions, Fusions, Rachats

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 juil. 2025, 23:43 UTC

Acquisitions, Fusions, Rachats

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 juil. 2025, 23:00 UTC

Acquisitions, Fusions, Rachats

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 juil. 2025, 22:38 UTC

Acquisitions, Fusions, Rachats

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 juil. 2025, 23:44 UTC

Market Talk

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Fall as Yen Strengthens -- Market Talk

16 juil. 2025, 23:24 UTC

Market Talk

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 juil. 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 juil. 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

Santos Cuts Top End of 2025 Production Guidance

16 juil. 2025, 23:17 UTC

Acquisitions, Fusions, Rachats

Santos: Production Recovery Underway in Cooper Basin

16 juil. 2025, 23:17 UTC

Acquisitions, Fusions, Rachats

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 juil. 2025, 23:17 UTC

Acquisitions, Fusions, Rachats

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 juil. 2025, 23:16 UTC

Acquisitions, Fusions, Rachats

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 juil. 2025, 23:16 UTC

Acquisitions, Fusions, Rachats

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 juil. 2025, 23:13 UTC

Acquisitions, Fusions, Rachats

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 juil. 2025, 23:13 UTC

Acquisitions, Fusions, Rachats

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 juil. 2025, 23:12 UTC

Acquisitions, Fusions, Rachats

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 juil. 2025, 23:12 UTC

Acquisitions, Fusions, Rachats

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 juil. 2025, 23:11 UTC

Acquisitions, Fusions, Rachats

Santos 2Q Free Cash Flow From Operations US$620 Million

16 juil. 2025, 23:11 UTC

Acquisitions, Fusions, Rachats

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 juil. 2025, 23:11 UTC

Acquisitions, Fusions, Rachats

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 juil. 2025, 23:11 UTC

Acquisitions, Fusions, Rachats

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 juil. 2025, 23:11 UTC

Acquisitions, Fusions, Rachats

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 juil. 2025, 22:43 UTC

Market Talk

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 juil. 2025, 22:35 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

16 juil. 2025, 22:35 UTC

Market Talk
Résultats

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 juil. 2025, 22:33 UTC

Market Talk
Résultats

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 juil. 2025, 22:28 UTC

Market Talk
Résultats

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 juil. 2025, 22:22 UTC

Market Talk
Résultats

Market Talk Roundup: Latest on U.S. Politics

16 juil. 2025, 22:22 UTC

Market Talk
Résultats

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Comparaison

Variation de prix

Zai Lab Ltd ADR prévision

Objectif de Prix

By TipRanks

64.93% hausse

Prévisions sur 12 Mois

Moyen 58.04 USD  64.93%

Haut 75 USD

Bas 38.2 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

5

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

28.13 / 31.12Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.